Nucleic acid therapeutics cdmo market revenue in 2023 | USD 245.0 million |
Market revenue in 2030 | USD 534.1 million |
Nucleic acid therapeutics cdmo market growth rate | 11.8% (CAGR from 2023 to 2030) |
Largest segment | Rna-based therapies |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, RNA-based Therapies |
Key market players worldwide | Catalent Inc, Thermo Fisher Scientific Inc, Lonza Group Ltd, FUJIFILM Holdings Corp, Charles River Laboratories International Inc, Eurofins Scientific SE, PerkinElmer, Oxford Biomedical Research, Danaher Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nucleic acid therapeutics cdmo market will help companies and investors design strategic landscapes.
Rna-based therapies was the largest segment with a revenue share of 65.67% in 2023. Horizon Databook has segmented the Mexico nucleic acid therapeutics cdmo market based on gene therapy, rna-based therapies covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico nucleic acid therapeutics cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Mexico nucleic acid therapeutics cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account